About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 864 record(s)
Req # A-2023-00024
Provide the final acknowledgment from the CNSC that the Class IA nuclear facility known as the Pool Test Reactor at the Chalk River Laboratories has been decommissioned including the final application for licence to decommission the same and the final licensing decision by the Commission.Organization: Canadian Nuclear Safety Commission
170 page(s)
July 2023
July 2023
Req # A-2023-00025
Provide every final Harassment and Violence investigation report completed between April 1, 2021 to March 31, 2023. These reports are prepared in accordance with the Work Place Harassment and Violence Prevention Regulations. They are typically held by Human Resources officials (e.g., OHS, Labour Relations, Values and Ethics) in headquarters and regions. Section 30 (2) of the Work Place Harassment and Violence Prevention Regulations states that: "An investigator’s report must not reveal, directly or indirectly, the identity of persons who are involved in an occurrence or the resolution process for an occurrence under these Regulations." As such, there should be little to no ATIP vetting required as these reports are already anonymized.Organization: Canadian Nuclear Safety Commission
20 page(s)
July 2023
July 2023
Req # A-2023-00029
The minutes of the CNSC’s Management Committee for May 2023.Organization: Canadian Nuclear Safety Commission
2 page(s)
July 2023
July 2023
Req # A-2023-00032
I hereby request the financial guarantee submitted as required by section 3 (1) (l) of the General Nuclear Safety and Control Regulations for licence number 15193-4-26.1.Organization: Canadian Nuclear Safety Commission
0 page(s)
July 2023
July 2023
Req # A-2023-00033
2198802 Ontario Inc. in Trust for a Corporation to be Incorporated (the “Purchaser”) purchase from A. Campagna Holdings Inc. (the “Vendor”) PT LT 280 PL 1960 VAUGHAN AS IN RH48890; EXCEPT PT 1, YR2257526; T/W RH48890; S/T TEMP EASE FOR A PERIOD OF 4 YRS COMMENCING UPON THE REGISTRATION OFTHIS PLAN OVER PT 2, YR2257526 AS IN YR2257526; SUBJECT TO A TEMPORARY EASEMENT UNTIL 2021/04/30 OVER PART 1, EXPROPRATION PLAN YR2813933 COMMENCING 2019/02/15 AS IN YR2813933; TOWN OF RICHMOND HILL (being all of PIN 03108-0815 (LT)) Address: 9190 Yonge Street, Richmond Hill, Ontario, L4C 7A2 (the “Property”)Organization: Canadian Nuclear Safety Commission
0 page(s)
July 2023
July 2023
Req # A-2023-00034
172 Drewry Towns LP (the “Purchaser”) purchase from Ellen Tannous and Matthews Tannous (the “Vendor”) of the lands and premises legally described on as PT LT 22 PL 7166 NORTH YORK AS IN TB965354; TORONTO (N YORK) ; CITY OF TORONTO (being all of PIN 10151-0175 (LT)) and municipally known as 202 Drewry Avenue, Toronto, Ontario, M2M 1E4 (the “Property”)Organization: Canadian Nuclear Safety Commission
0 page(s)
July 2023
July 2023
Req # A-2023-00035
1000363494 Ontario Inc. (the “Purchaser”) purchase from 1473990 Ontario Inc. (the “Vendor”) PT TWP LT 178 STAMFORD, PT 5 PL 59R11584 EXCEPT PT 3 PL 59R13955; S/T EASE OVER PT 2 PL 59R13955 IN FAV PT 6 & 7 PL 59R11584 AS IN SN254241; T/W EASEOVER PT 1 59R13955 AS IN SN254241; T/W EASE OVER PT 1 PL 59R11736 IN FAV PT 5 PL 59R11584 AS IN RO775517; TOGETHER WITH AN EASEMENT OVER PT TWP LT 178STAMFORD PT 2, 59R14156 UNTIL 2031/03/15 AS IN SN274538; TOGETHER WITH AN EASEMENT OVER PT 2 59R-11736 AS IN RO821226; CITY OF NIAGARA FALLS; being all of PIN 64461-0084 (LT) Address: Oakwood Drive, Niagara Falls, Ontario L2E 6S5 (Vacant Land) (the “Property)Organization: Canadian Nuclear Safety Commission
0 page(s)
July 2023
July 2023
Req # A-2022-05111
Electronic copies of the following documents. In all cases, cabinet confidences may be excluded and draft versions of documents. In all of the requests below, “draft guidelines” refers to the PMPRB Guidelines that were published for comment on October 6, 2022, or any prior drafts or versions of those 2022 Guidelines (for example, if a draft version was circulated to Health Canada for comment in September 2022, it would be part of the “draft guidelines” for the purpose of this request). • Emails or other communications from Health Canada commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Emails or other communications from the Board members or Board Chair commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Any training presentations, training manuals, or summaries of the new guidelines prepared for use by the Board Staff, Board, or other governmental departments prepared between July 1, 2022, and October 6, 2022. • Any documents with calculations of how much prices will decrease under the draft guidelines, or under alternative pricing rules, and that were prepared between January 1, 2022, and October 6, 2022 (note the change in date relative to other requests). • Any documents comparing prices or price reductions under the draft guidelines and the old PMPRB Compendium of Guidelines and Procedures. • Any documents, including legal memos, on the compliance of the draft guidelines with legal decisions about the PMPRB, including Alexion Pharmaceuticals Inc. v. Canada (Attorney General), 2021 FCA 157, Merck Canada c Canada, 2022 QCCA 240, and Innovative Medicines Canada v. Canada (Attorney General), 2020 FC 725. • Any documents which discuss how a medicine’s therapeutic class and comparator products will be established under the draft guidelines. • Any documents showing how the Board Staff arrived at the exact pricing tests discussed in paragraph 33-35 of the draft Guidelines. • Any documents which discuss how Board Staff will assess whether a price is excessive *after* an investigation has been opened. For context, the backgrounder which accompanied the draft guidelines suggested that staff will consider “the totality of the circumstances surrounding the price of the medicine, through the lens of the section 85 factors.Organization: Patented Medicine Prices Review Board Canada
197 page(s)
July 2023
July 2023
Req # A-2023-025211
With regard to the c. 2003 HDAP Report on New Patented Drug - Angiomax (http://www.pmprbcepmb.gc.ca/view.asp?ccid=583), I am looking for a copy of any supporting research, reports and calculations used to determine dosage regimens. I am specifically interested in how these quantities (in mL) were derived, the benchmark patient weight that was used (in kg) and the timeframe of the dosing.Organization: Patented Medicine Prices Review Board Canada
18 page(s)
July 2023
July 2023
Req # A-2023-025599
For FY 2015-2022 (inclusive), how many investigations into prescription pricing on the basis that the pricing exceeded the guidelines resulted in a public hearing? Of those that resulted in a public hearing, in how many was the pricing found to be excessive? Of those that were found to be excessive, how many resulted in orders to reduce the prescription price?Organization: Patented Medicine Prices Review Board Canada
1 page(s)
July 2023
July 2023